Меню
Идёт набор NCT06805734

Natural History With Focus on Oncological Risk Evaluation in Pediatric Patients With PTEN Pathogenic Variants

Наблюдательное PTEN Hamartoma Syndrome

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: PTEN Hamartoma Syndrome. Базовые параметры: до 17 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Италия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Natural History With Focus on Oncological Risk Evaluation in Pediatric Patients With PTEN Pathogenic Variants - Observational Study

Обзор

This is an observational study in pediatric patientis carryng PTEN pathogenic variants aimed to define oncological risk in children and provide a deeper insight of the clinical course, establishing an updated follow-up protocol.

Подробное описание

PTEN is a tumor suppressor gene that was first linked to cancer predisposition syndromes but, in the following years, its phenotypic spectrum has been in continuous evolution and expansion, and nowadays we know that pathogenic variants n this gene may also be found in children presenting with Autism Spectrum Disorder (ASD), and/or DD and macrocephaly, or also with macrocephaly alone. Thus, the term PTEN Hamartoma Tumor Syndrome (PTHS) is now used when referring to PTEN-related conditions.

Nowadays, there is no recognized standard protocol for pediatric follow-up. The screening in mostly single-Centre-based and generally not performed in infancy, with large variability in protocols and timing.

The penetrance, which was previously believed to follow an age-related pattern, nowadays seems rather to be age-specific, as children mainly present macrocephaly and neuropsychiatric problems (DD/ASD), while adults are diagnosed mostly because of gastrointestinal malignancies, breast cancer, thyroid carcinoma or other tumors. However, it is not always true that adult symptoms never occur in PTHS children and, conversely, pediatric signs may also persist through adulthood.

The present study aims to collect PTEN mutated patients and their relatives diagnosed in Italy and followed in different Centers, offering a large pediatric cohort with a full clinical description and trying to provide a deeper insight of the clinical course and oncological manifestations of PTEN-related syndrome; we would like to establish an updated follow-up protocol in order to address all the possible clinical needs of these children.

Первичные конечные точки

  • Rate of tumor onset in the pediatric subjects with PTEN pathogenic variants [Срок оценки: 5 years]
  • Rate of tumor onset in the adult relatives of the pediatric subjects also carrying the PTEN pathogenic variant [Срок оценки: 5 years]
Вторичные конечные точки (5)
  • Rate of major malformations [Срок оценки: 5 years]
  • Rate of incidence of brain MRI anomalies [Срок оценки: 5 years]
  • Rate of incidence of neurological comorbidities [Срок оценки: 5 years]
  • Rate of incidence of neurodevelopmental disorders [Срок оценки: 5 years]
  • To analyze Head Circumferences and development of growth HC curves in PTEN patients (data of affected parents will be also recorded) [Срок оценки: 5 years]

Критерии участия

Критерии включения

  • PTEN pathogenic variants (class 4/5 SNV, gene deletion, intragenic duplication/deletion)
  • Pediatric patients (<18 years old) and their affected relatives, male/female, all ethnicities
  • The legal representative must agree to follow the screening protocol
  • Informed consent signed by the legal representative

Критерии исключения

  • Refuse to undergo the exams of the protocol assessment at the diagnosis
  • PTEN non-pathogenic variants (VOUS or benign/likely benign vatiants)
  • No signed informed consent

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Только случаи

Центры проведения

Италия · 1 центр
  • Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan

Публикации

  • Compton-Smith RN, Fawcett JW. Systemic lupus erythematosus associated with procainamide. Br J Clin Pract. 1967 May;21(5):248-51. No abstract available. PMID 6046409
  • Chen CY, Chen J, He L, Stiles BL. PTEN: Tumor Suppressor and Metabolic Regulator. Front Endocrinol (Lausanne). 2018 Jul 9;9:338. doi: 10.3389/fendo.2018.00338. eCollection 2018. PMID 30038596
  • Rademacher S, Eickholt BJ. PTEN in Autism and Neurodevelopmental Disorders. Cold Spring Harb Perspect Med. 2019 Nov 1;9(11):a036780. doi: 10.1101/cshperspect.a036780. PMID 31427284

Идентификаторы

NCT: NCT06805734 · PTEN_Ped

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗